Effectiveness of a Cognitive Training Program (UMAM Method) in Elderly People Without Dementia
25. Januar 2020 aktualisiert von: Madrid Salud
Cognitive Training in Elders Without Dementia Using UMAM Method. Genetic, Brain Volume and Cognitive Reserve Predictors: A Randomized Controlled Study
The study is oriented to analyze the effectiveness of a cognitive training method (UMAM) on cognitive functions, subjective memory and mood state in elderly people without dementia.
On the other hand, the study aims to examine whether variables such as cognitive reserve (e.g.
educational level), APOE genotype and intracranial volume are related to increased benefit after the intervention.
The researchers hope to find that greater cognitive reserve, not having the APOE allele ε4, and a greater volume of memory-related brain areas, are associated with better outcomes after the cognitive intervention.
Studienübersicht
Status
Abgeschlossen
Bedingungen
Intervention / Behandlung
Studientyp
Interventionell
Einschreibung (Tatsächlich)
199
Phase
- Unzutreffend
Kontakte und Standorte
Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.
Studienorte
-
-
-
Madrid, Spanien, 28006
- Centro de Prevención del Deterioro Cognitivo
-
-
Teilnahmekriterien
Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.
Zulassungskriterien
Studienberechtigtes Alter
60 Jahre und älter (Erwachsene, Älterer Erwachsener)
Akzeptiert gesunde Freiwillige
Nein
Studienberechtigte Geschlechter
Alle
Beschreibung
Inclusion Criteria:
- Being over 60 years old.
- Having a global cognitive performance > 23 in the Mini Mental State Examination Test.
- Having no history of neurological or serious psychiatric disorders (severe psycho-affective disorders and psychosis or other psychiatric disorders like alcoholism).
Exclusion Criteria:
- Chronic use of anxiolytics.
- Chronic use of neuroleptics.
- Chronic use of anticonvulsants.
- Having hearing or vision impairments that would preclude testing.
- Magnetic Resonance Imaging (MRI) contraindications.
Studienplan
Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Verhütung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Experimental Group
The experimental group carried out a 30-session multi-factorial group memory training program (UMAM method), with a frequency of three weekly sessions of 90 minutes each. The training program consists of four modules: 1- Stimulation of cognitive processes; learning and practicing internal memory strategies and solving everyday forgetfulness; 2- Instruction in basic concepts about memory; 3- Intervention on daily living and forgetting experiences, using internal and external strategies to solve everyday memory failures; 4- Metacognition or metamemory: the subjects were to reflect about their cognitive failures by analyzing the causes and variables of those failures. In addition, the experimental group followed the standard activities in which all users attending the Center are involved (planned interviews, dialogue-conferences, general health recommendations, etc.). |
|
|
Kein Eingriff: Control Group
The Control Group followed the standard activities in which all users attending the Center are involved (planned interviews, dialogue-conferences, general health recommendations, etc.).
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Change in general cognition
Zeitfenster: This cognitive variable was assessed before and after the intervention. The interval between the pre and post-intervention assessment was 6 months.
|
The measure of the post-intervention change in general cognition, assessed with the Mini Mental State Examination Test (MMSE) and the 7 Minutes Test (7M).The score ranges from 0 to 30 points (MMSE) and from 0 to 89 points (7M).
In both cases, the higher scores indicate a better outcome.
|
This cognitive variable was assessed before and after the intervention. The interval between the pre and post-intervention assessment was 6 months.
|
|
Change in verbal memory
Zeitfenster: This cognitive variable was assessed before and after the intervention. The interval between the pre and post-intervention assessment was 6 months.
|
The measure of the post-intervention change in verbal memory, assessed with the Word List Test of the Wechsler Memory Scale-III.
The score ranges from 0 to 48 points.
Higher scores indicate a better outcome.
|
This cognitive variable was assessed before and after the intervention. The interval between the pre and post-intervention assessment was 6 months.
|
|
Change in logical memory
Zeitfenster: This cognitive variable was assessed before and after the intervention. The interval between the pre and post-intervention assessment was 6 months.
|
The measure of the post-intervention change in immediate and delayed logical memory, assessed with the Logical Memory Test (immediate and delayed units) of the Wechsler Memory Scale-III.
The score ranges from 0 to 75 points (immediate units) and from 0 to 50 (delayed units).
Higher scores indicate a better outcome.
|
This cognitive variable was assessed before and after the intervention. The interval between the pre and post-intervention assessment was 6 months.
|
|
Change in visual memory
Zeitfenster: This cognitive variable was assessed before and after the intervention. The interval between the pre and post-intervention assessment was 6 months.
|
The measure of the post-intervention change in visual memory, assessed with the Rey memory test (form B).
The score ranges from 0 to 22 points.
Higher scores indicate a better outcome.
|
This cognitive variable was assessed before and after the intervention. The interval between the pre and post-intervention assessment was 6 months.
|
|
Change in daily memory
Zeitfenster: This cognitive variable was assessed before and after the intervention. The interval between the pre and post-intervention assessment was 6 months.
|
The measure of the post-intervention change in daily memory, assessed with the Rivermead Behavioral Memory Test.
The score ranges from 0 to 24 points.
Higher scores indicate a better outcome.
|
This cognitive variable was assessed before and after the intervention. The interval between the pre and post-intervention assessment was 6 months.
|
|
Change in attentional amplitude
Zeitfenster: This cognitive variable was assessed before and after the intervention. The interval between the pre and post-intervention assessment was 6 months.
|
The measure of the post-intervention change in attentional amplitude, assessed with the Direct Digit Test of the Wechsler Memory Scale-III.
The score ranges from 0 to 16 points.
Higher scores indicate a better outcome.
|
This cognitive variable was assessed before and after the intervention. The interval between the pre and post-intervention assessment was 6 months.
|
|
Change in attentional control
Zeitfenster: This cognitive variable was assessed before and after the intervention. The interval between the pre and post-intervention assessment was 6 months.
|
The measure of the post-intervention change in attentional control, assessed with the Inverse Digit Test of the Wechsler Memory Scale-III.
The score ranges from 0 to 14 points.
Higher scores indicate a better outcome.
|
This cognitive variable was assessed before and after the intervention. The interval between the pre and post-intervention assessment was 6 months.
|
|
Change in attention and processing speed
Zeitfenster: This cognitive variable was assessed before and after the intervention. The interval between the pre and post-intervention assessment was 6 months.
|
The measure of the post-intervention change in attention, assessed with the Trail Making Test, form A. The score ranges from 0 to 200 points.
Higher scores indicate a worse outcome.
|
This cognitive variable was assessed before and after the intervention. The interval between the pre and post-intervention assessment was 6 months.
|
|
Change in alternating attention and planning
Zeitfenster: This cognitive variable was assessed before and after the intervention. The interval between the pre and post-intervention assessment was 6 months.
|
The measure of the post-intervention change in alternating attention and planning, assessed with the Trail Making Test, form B. The score ranges from 0 to 400 points.
Higher scores indicate a worse outcome.
|
This cognitive variable was assessed before and after the intervention. The interval between the pre and post-intervention assessment was 6 months.
|
|
Change in naming ability (language)
Zeitfenster: This cognitive variable was assessed before and after the intervention. The interval between the pre and post-intervention assessment was 6 months.
|
The measure of the post-intervention change in naming ability, assessed with the Boston Naming Test.
The score ranges from 0 to 60 points.
Higher scores indicate a better outcome.
|
This cognitive variable was assessed before and after the intervention. The interval between the pre and post-intervention assessment was 6 months.
|
|
Change in verbal fluency (language)
Zeitfenster: This cognitive variable was assessed before and after the intervention. The interval between the pre and post-intervention assessment was 6 months.
|
The measure of the post-intervention change in phonologic and semantic verbal fluency, assessed with the Phonological Verbal Fluency Test and the Semantic Fluency Test respectively.
The score goes from zero onwards (there is no upper limit).
Higher scores indicate a better outcome.
|
This cognitive variable was assessed before and after the intervention. The interval between the pre and post-intervention assessment was 6 months.
|
|
Change in subjective memory
Zeitfenster: This variable was assessed before and after the intervention. The interval between the pre and post-intervention assessment was 6 months.
|
The measure of the post-intervention change in Subjective Memory, assessed with the Memory Failures of Everyday Questionnaire.The score ranges from 0 to 56 points.
Higher scores indicate a worse outcome.
|
This variable was assessed before and after the intervention. The interval between the pre and post-intervention assessment was 6 months.
|
|
Change in mood
Zeitfenster: This variable was assessed before and after the intervention. The interval between the pre and post-intervention assessment was 6 months.
|
The measure of the post-intervention change in mood, assessed with the Geriatric Depression Scale.
The score ranges from 0 to 15 points.
Higher scores indicate a worse outcome.
|
This variable was assessed before and after the intervention. The interval between the pre and post-intervention assessment was 6 months.
|
|
The Cognitive Reserve as a predictor of change.
Zeitfenster: Cognitive Reserve was assessed in the pre-intervention assessment.
|
The Cognitive Reserve was assessed with Rami Test.
The score ranges from 0 to 25 points.
|
Cognitive Reserve was assessed in the pre-intervention assessment.
|
|
The Genetic Profile as a predictor of change.
Zeitfenster: The Genetic Profile was assessed in the pre-intervention assessment.
|
The Genetic Profile was obtained by genetic analysis employing a blood test.
APOE gene has been coded as 1 (meaning no ε4 allele), or 0 (for at least one ε4 allele).
|
The Genetic Profile was assessed in the pre-intervention assessment.
|
|
The Brain Volume as a predictor of change.
Zeitfenster: The Brain Volume was assessed in the pre-intervention assessment.
|
The Brain Volume (total gray volume, left hippocampus, right hippocampus and total intracranial volume) was assessed by magnetic resonance imaging.
Unit of measure: mm3.
|
The Brain Volume was assessed in the pre-intervention assessment.
|
Mitarbeiter und Ermittler
Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.
Studienaufzeichnungsdaten
Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.
Haupttermine studieren
Studienbeginn (Tatsächlich)
1. Oktober 2013
Primärer Abschluss (Tatsächlich)
1. Mai 2015
Studienabschluss (Tatsächlich)
1. Mai 2015
Studienanmeldedaten
Zuerst eingereicht
22. Dezember 2019
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
25. Januar 2020
Zuerst gepostet (Tatsächlich)
29. Januar 2020
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
29. Januar 2020
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
25. Januar 2020
Zuletzt verifiziert
1. Januar 2020
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 15/382-E_BS
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Nein
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Nein
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Nein
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Nein
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Altersbedingte Gedächtnisstörungen
-
Hospices Civils de LyonAbgeschlossenNeuromyelitis-Optica-Spektrum-Erkrankungen | Neuromyelitis optica Spectrum Related DisordersFrankreich